- Last edited on April 15, 2024
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Next revision Both sides next revision | ||
|
child:adhd [on April 15, 2024] psychdb [Pharmacotherapy: Outcomes] |
child:adhd [on April 15, 2024] psychdb [Pharmacotherapy: Monitoring] |
||
|---|---|---|---|
| Line 504: | Line 504: | ||
| </panel> | </panel> | ||
| ==== Pharmacotherapy: Monitoring==== | ==== Pharmacotherapy: Monitoring==== | ||
| + | <alert type="info" icon="fa fa-book fa-lg fa-fw"> | ||
| + | See also: **[[https://pediatrics.aappublications.org/content/122/2/451|Perrin, James M., et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122.2 (2008): 451-453.]]** | ||
| + | </alert> | ||
| <WRAP group> | <WRAP group> | ||
| <WRAP half column> | <WRAP half column> | ||
| - | |||
| Having an approach to prescribing can help the clinician assess whether a medication is working, and provides a systematic approach to monitoring prescribing: | Having an approach to prescribing can help the clinician assess whether a medication is working, and provides a systematic approach to monitoring prescribing: | ||
| - Start the medication on weekend so parents can see how the child responds to the drug throughout the day (not on a school day!) | - Start the medication on weekend so parents can see how the child responds to the drug throughout the day (not on a school day!) | ||
| Line 545: | Line 547: | ||
| </mobiletable> | </mobiletable> | ||
| </panel> | </panel> | ||
| - | |||
| - | <panel type="info" title="Common Side Effects in ADHD Medications" subtitle="Adapted from: Canadian ADHD Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines, Fourth Edition, Toronto ON; CADDRA, 2018" no-body="true"> | ||
| - | <mobiletable 1> | ||
| - | ^ ^ Stimulant ^ Atomoxetine ^ Alpha-2 Agonist ^ | ||
| - | ^ Hypotension (BP ↓) and Bradycardia (HR ↓) | - | - | ✓ | | ||
| - | ^ Hypertension (BP ↑ 5 mmHg) and Tachycardia (HR ↑ 10bpm) | ✓ | ✓ | When stopped suddenly (rebound hypertension) | | ||
| - | ^ Appetite supression | ✓ | ✓ | Low incidence | | ||
| - | ^ Constipation/diarrhea | ✓ | ✓ | ✓ | | ||
| - | ^ Dry mouth | ✓ | ✓ | ✓ | | ||
| - | ^ GI upset | ✓ | ✓ | Upper abdominal pain | | ||
| - | ^ Nausea/vomitting | ✓ | ✓ | ✓ | | ||
| - | ^ Anxiety | ✓ | ✓ | Low incidence | | ||
| - | ^ Dizziness | ✓ | - | - | | ||
| - | ^ Dysphoria/irritability | ✓ | ✓ | Uncommon | | ||
| - | ^ Headache | ✓ | ✓ | **Yes** | | ||
| - | ^ Initial insomnia | ✓ | ✓ | Low incidence | | ||
| - | ^ Rebound effect | ✓ | - | - | | ||
| - | ^ Tics | ✓ | Uncommon | - | | ||
| - | ^ Weight loss | ✓ | ✓ | - | | ||
| - | ^ Sexual dysfunction | Uncommon | ✓ | - | | ||
| - | ^ Skin reactions | ✓ | ✓ | Low incidence | | ||
| - | </mobiletable> | ||
| - | </panel> | ||
| - | |||
| - | <alert type="info" icon="fa fa-book fa-lg fa-fw"> | ||
| - | See also: **[[https://pediatrics.aappublications.org/content/122/2/451|Perrin, James M., et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122.2 (2008): 451-453.]]** | ||
| - | </alert> | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| ==== Pharmacotherapy: Side Effects and Adverse Events ==== | ==== Pharmacotherapy: Side Effects and Adverse Events ==== | ||
| <callout type="info" title="Stimulants and the Risk of Psychosis and Mania" icon="true"> | <callout type="info" title="Stimulants and the Risk of Psychosis and Mania" icon="true"> | ||